icon-folder.gif   Conference Reports for NATAP  
 
  17th International Workshop
on Clinical Pharmacology of
HIV and Hepatitis Therapy
June 8-10, 2016, Washington DC
Back grey_arrow_rt.gif
 
 
 
Raltegravir (RAL) Pharmacokinetics (PK) and Safety in HIV-1 Exposed Neonates at High Risk of Infection (IMPAACT P1110)
 
 
  Reported by Jules Levin
17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy June 8-10, 2016, Washington, DC, USA
 
D.F. Clarke1, E.P. Acosta2, A. Chain3, J. Wang4, S.A. Spector5, Y.J. Bryson6, H. Teppler7, S. Popson8, B. Graham8, M.E. Smith9, R. Hazra10, M. Mirochnick11
 
1Boston Medical Center, Pediatric Infectious Diseases, Boston, USA; 2Univ of Alabama at Birmingham, Pharmacology and Toxicology, Birmingham, USA; 3Merck Research Laboratories, Pharmacology, North Wales, USA; 4Harvard School of Public Health, Biostatistics, Boston, USA; 5Univ of California at San Diego, Pediatrics, San Diego, USA; 6Univ of California at Los Angeles, Pediatrics, Los Angeles, USA; 7Merck Research Laboratories, Clinical Research, North Wales, USA; 8FSTRF, Research, Amherst, USA; 9NIH, NIAID, Bethesda, USA; 10NIH, NICHD, Bethesda, USA; 11Boston University, Pediatrics, Boston, USA

Pharm1

Pharm2

Pharm3

Pharm4

Pharm5

Pharm6

Pharm7

Pharm8